Infantile Haemangiomas Referred to Paediatric Surgery: Referral Patterns and Clinical Outcomes

Background: Infantile haemangiomas (IH) are the most common benign vascular tumours during childhood. Most are small, uncomplicated and undergo spontaneous involution, requiring no specific treatment. However, a minority may develop complications such as ulceration, bleeding, infection or pain, with potential functional impairment or permanent sequelae. Early identification of high-risk IH and timely specialist assessment are therefore essential. This study aimed to characterise children referred to paediatric surgery for suspected IH, focusing on clinical presentation, referral timing, management and potential need for surgical intervention.

Methods: A retrospective observational study was conducted including children aged 0-17 years attending their first paediatric surgery appointment in 2025 who were diagnosed with an IH or another vascular anomaly. Patients already being followed for these conditions were excluded. Demographic and clinical characteristics, diagnostic findings and management were described and analysed.

Results: A total of 85 children attending their first paediatric surgery appointment were included, of whom 53/85 (62.4%) were female. The main referral source was primary care with 51/85 cases (60.0%), followed by Neonatology with 15/85 children (17.6%). Overall, 63/85 patients (74.1%) were diagnosed with IH, while the remaining children had other vascular anomalies. Among patients with confirmed IH, median age at first assessment was 6 months (IQR 3.5–11.5). Only 16/63 (25.4%) were assessed within the first 3 months of life, while 28/63 (44.4%) were assessed after 6 months. Among patients with available gestational age data, 17/31 (54.8%) were born preterm. About 50.8% of the cases (32/63) required no specific treatment. Topical timolol was prescribed in 16/63 (25.4%) and systemic propranolol in 12/63 (19.0%). Complications were documented in 3/63 (4.8%) patients, all of whom required treatment. Surgical intervention was performed in only 3/63 (4.8%) patients. Children requiring treatment were assessed significantly earlier than those requiring no treatment (median 4 vs 8.5 months; p<0.001). Median age at first assessment was 3 months among patients receiving propranolol, 5 months among those receiving timolol and 8.5 months among those requiring no treatment (p<0.001).

Conclusions: Most IH referred to paediatric surgery did not require surgical intervention and just over half were managed conservatively without specific treatment. Children requiring treatment were assessed significantly earlier, particularly those receiving systemic therapy with oral propranolol. Although most IH do not require specific treatment, these findings support the importance of early risk stratification and structured referral models to paediatric surgery. Referral of high-risk IH should ideally occur during the proliferative phase, particularly within the first 6 months of life, when treatment with propranolol is most effective. Earlier assessment and initiation of therapy, when indicated, may further optimise outcomes, as the potential benefit of propranolol is greater when started at younger ages. Establishing clear referral criteria may help identify and prioritise high-risk IH and ensure timely specialist assessment while reducing unnecessary referrals and the risk of preventable complications or sequelae.